THE WOODLANDS, Texas,
April 28 /PRNewswire-FirstCall/ --
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical
company focused on discovering breakthrough treatments for human
disease, announced today that Alan Main, Ph.D., Lexicon's executive
vice president of pharmaceutical research, will present at the BIO
International Convention in Chicago,
Illinois on Wednesday, May 5,
2010 at 3:30 p.m. Central
Time. The presentation will provide an overview of Lexicon's
clinical development programs, corporate objectives and business
strategy.
The BIO International Convention is the largest global event for
the biotechnology industry and attracts the biggest names in
biotech, offers key networking and partnering opportunities, and
provides insights and inspiration on the major trends affecting the
industry.
About Lexicon
Lexicon is a biopharmaceutical company focused on discovering
and developing breakthrough treatments for human disease.
Lexicon currently has four drug candidates in mid-stage
development for diabetes, irritable bowel syndrome, carcinoid
syndrome and rheumatoid arthritis, all of which were discovered by
Lexicon's research team. Lexicon has used its proprietary
gene knockout technology to identify more than 100 promising drug
targets. Lexicon has focused drug discovery efforts on these
biologically-validated targets to create its extensive pipeline of
clinical and preclinical programs. For additional information
about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements,"
including statements relating to Lexicon's growth and
future operating results, discovery and development of products,
strategic alliances and intellectual property, as well as other
matters that are not historical facts or information. All
forward-looking statements are based on management's current
assumptions and expectations and involve risks, uncertainties and
other important factors, specifically including those
relating to Lexicon's ability to successfully conduct preclinical
and clinical development of its potential drug candidates, advance
additional candidates into preclinical and clinical development,
obtain necessary regulatory approvals, achieve its operational
objectives, obtain patent protection for its discoveries and
establish strategic alliances, as well as additional factors
relating to manufacturing, intellectual property rights, and the
therapeutic or commercial value of its drug candidates, that
may cause Lexicon's actual results to be materially different from
any future results expressed or implied by such forward-looking
statements. Information identifying such important factors is
contained under "Factors Affecting Forward-Looking Statements" and
"Risk Factors" in Lexicon's annual report on Form 10-K for the year
ended December 31, 2009, as filed
with the Securities and Exchange Commission. Lexicon
undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
SOURCE Lexicon Pharmaceuticals, Inc.